Related Experiment Video
Updated: Aug 13, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Aberrant T helper cell response in tumor-bearing mice limits the efficacy of dendritic cell vaccine
John Y Kao1, Min Zhang, Chuan-Min Chen
1Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109-0682, USA. jykao@umich.edu
Abstract:
Dendritic cell (DC) vaccine is a promising immunotherapy for malignancies, but its clinical efficacy has been questioned. Here we examined the mechanisms of treatment failure with DC vaccine in a murine colon cancer model. DC vaccination of naive mice prevents tumor implantation, but it is ineffective in tumor-bearing hosts despite the induction of tumor-specific CTL activity. Analyses of tumor-specific T helper cell type 1 (Th1)/T helper cell type 2 (Th2) responses showed that DC vaccine induced a mixed Th1/Th2 response in naive mice. Interestingly, CD4+ T cells from tumor-bearing mice showed a Th1-predominant response before DC vaccination but Th2 after DC vaccination. Furthermore, interleukin-10 production was higher in CD4+ T cells from vaccinated tumor-bearing mice than in CD4+ T cells from unvaccinated tumor-bearing mice. CD4+ T cells from mice treated with lipopolysaccharide (LPS)-matured DC fusion vaccine had lower production of interleukin-10 than CD4+ T cells from mice treated with non-LPS-treated DC vaccine. However, similar to the non-LPS-treated DC vaccine, the LPS-matured DC vaccine failed to suppress tumor growth and induced a Th2 predominant tumor-specific response in tumor-bearing mice. These results suggest that the presence of tumor in the host induces an aberrant CD4+ T cell response to DC vaccine, which may contribute to the failure of the vaccine to eradicate established tumors.
Insights
Dendritic cell (DC) vaccines show promise but fail in established cancers. Tumor presence alters T cell responses, shifting from Th1 to Th2, hindering vaccine efficacy and tumor eradication.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Dendritic cell (DC) vaccines are a potential immunotherapy for cancers.
- However, their clinical effectiveness against established tumors remains uncertain.
- Understanding treatment failure mechanisms is crucial for improving cancer immunotherapies.
Purpose of the Study:
- To investigate why dendritic cell (DC) vaccines fail in tumor-bearing hosts.
- To analyze the impact of tumor presence on anti-tumor immune responses after DC vaccination.
- To identify immune modulations contributing to DC vaccine inefficacy.
Main Methods:
- Utilized a murine colon cancer model to assess DC vaccine efficacy.
- Analyzed tumor-specific T helper cell type 1 (Th1) and T helper cell type 2 (Th2) responses.
- Measured interleukin-10 production in CD4+ T cells from vaccinated and unvaccinated tumor-bearing mice.
Main Results:
- DC vaccination prevented tumor implantation in naive mice but was ineffective in tumor-bearing hosts.
- Tumor-bearing mice showed a shift from Th1 to Th2 predominant CD4+ T cell responses post-vaccination.
- Increased interleukin-10 production was observed in vaccinated tumor-bearing mice, regardless of DC maturation (LPS-treated).
Conclusions:
- Established tumors induce aberrant CD4+ T cell responses to DC vaccines.
- This aberrant response, characterized by a Th2 shift and increased IL-10, likely contributes to vaccine failure.
- Further research is needed to overcome these tumor-induced immune suppressive mechanisms for effective DC vaccination.
Related Concept Videos
01:27Tumor Immunotherapy
01:40Cell-mediated Immune Responses